You just read:

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Feb 09, 2018, 06:00 ET